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Plerixafor (Mozobil) Guidance Algorithm
Evaluation Guidance
 Patients needing cells
for one transplant
(minimum 2.5 x10E6
CD34 cells/Kg) - mobilized
with G-CSF  Peripheral
CD34 checked on day 5
following 4 days of G-CSF.
 If CD34 number is\10 cells/ul,
give G-CSF post-procedure
and administer plerixafor that
evening. G-CSF will also be
given 1 hour pre-collection the
following morning.
 Patients needing more than
one transplant (minimum 5.0 x10E6
CD34 cells/Kg) mobilized
with G-CSF  Peripheral CD34
checked on day 5 following 4 days
of G-CSF.
 If CD34 number\20 cells/ul,
give G-CSF post procedure
and administer plerixafor that
evening. G-CSF will be given
1 hour pre-collection the
following morning.
 The first day collected product
contains LESS THAN one-half
of the desired dose of 2.5 x 10E6
CD34/Kg or 5.0 x 10E6 CD34/Kg.
 Give plerixafor that evening.
G-CSF will also be given
1 hour pre-collection the
following morning.
 Patients pretreated with lenalidomide
(more than 4 cycles).  Patients
with delayed count recovery from
prior therapy.  Other reasons for
high mobilization failure rate.
 Four days of G-CSF, then
plerixafor given on the fourth
evening. G-CSF will be given
1 hour pre-collection the
following morning.
* G-CSF is given at 10 mcg/kg for four days for mobilization; ** Plerixafor
is given at 240 mcg/kg per treatment.
Oral Presentations S165Our goal was to reduce the number of collections andmobilization
failures to achieve the desired CD34 dose, with optimal use of plerix-
afor. Options were to use it for all patients or to develop an algorithm
of when to add it to the primary mobilization regimen. Plerixafor is
not warranted for every patient due to its high cost; hence usage
that is fiscally beneficial was developed. This algorithm evaluates fac-
tors needed to use plerixafor as described in the table below. All col-
lections performed were 4-6 blood volume procedures.
FromApr. to Sept. 2009, 44 patients (Ages: 30-69;Dx: 22 MMand
22 NHL, HD; Sex: 26 M and 18 F) were considered for plerixafor
using this algorithm. Fifteen (Ages: 38-67; Dx: 7 MM and 8 NHL,
HD; Sex: 10 male and 5 female) of the 44 patients (34%) were given
plerixafor. Of the 15 patients, 5 (33%) were given plerixafor due to
low peripheral CD34 counts on day 1; 6 (40%) were given plerixafor
due to a collection of less than one-half of the desired collection goal
on day 1; and 4 (27%) were given plerixafor up-front. Fourteen of the
15 patients (93%) were able to collect during the first mobilization
attempt using this algorithm. The average number of collection
days for the plerixafor patients was 2.3 compared to 1.7 for the rest
of the patients not given plerixafor. Collectively, the number was
1.91 collection days per patient for time span evaluated. In years
2007-2008, the number of collection days was 2.68 days per patient,
27 of 137 patients (19.7%) required remobilization and 11 of 137
(8%) failed mobilization.
This approach has the potential to reduce the overall cost of PBSC
collections by reducing the number of collection days and avoiding
remobilization in a significant percentage of patients. Each extra
day of collection and each remobilization is an additional $8,000
to $10,000 expense for the patient. Other concerns are the possible
need for platelet transfusions with multiple collections and the pos-
sible delay in transplant increasing the risk of disease relapse. This
algorithmic approach providing for the optimal use of plerixafor
needs to be further evaluated with a larger number of patients.29
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Little is known about the additional benefit of Autologous Stem
Cell Transplantation (ASCT) as consolidation treatment of NHL
in 1st CR in HIV+ patients. We herein report a comparative analysis
of HIV+ patients with a LBCL treated with chemotherapy (chemo)
followed by ASCT and a matched cohort of HIV+ patients treated
with chemo alone.
Methodology:Retrospective, registry-based, matched cohort study.
ASCT cohort: patients with diffuse large B-cell (DLBC) or plasma-
blastic NHL treated with ASCT in 1st CR after standard chemo and
reported to the EBMT Registry. Chemo cohort: For each patient
within the ASCT cohort we selected two controls from the HIV+
patients with NHL GESIDA/PETHEMA registry. Patients in
both cohorts were in 1st CR following front-line or rescue (for
partially responding patients) chemo and were matched according
to histology, IPI and the use of Rituximab.We compared overall sur-
vival (OS), disease free survival (DFS) and cumulative incidence (CI)
of relapse between both cohorts. These primary outcomes were
defined according to the EBMT. OS was computed from diagnosis
while DFS and CI of relapse were computed from 3 weeks after
the last standard chemo cycle administered (end of chemo).
Results:The ASCT cohort included 10 patients diagnosed between
1999 and 2005. The Chemo cohort included 20 patients, 16 diag-
nosed between 1999 and 2005. Both cohorts were comparable for
the main clinical and patient features (Table 1). The median (range)
follow-up (FU) time since the end of chemo for surviving patients
was 56 months (mo) (24-106) in the ASCT cohort vs 37 mo (8-
107.5) in the Chemo cohort; P5.28. Five years (yr) OS for the
ASCT cohort and the Chemo cohort were 68.5% [CI95%: 39-98]
and 46.5% [CI95%: 18-75], respectively; P5.6. Three yr DFS for
the ASCT cohort and the Chemo cohort were 70% [CI95%: 41.5-
98.5] and 59.5% [CI95%: 29-86]; respectively; P5.4. The CI of re-
lapse in the ASCT cohort and the Chemo cohort were 21% [CI95%:
0-47] and 27% [CI95%: 2-51], respectively; P5.8
Conclusions: In this retrospective registry-based, matched co-
hort study of HIV+ patients with large B-cell NHL we found
a non-significant effect of ASCT as consolidation treatment in
1st CR patients, in terms of survival and relapse incidence. Nev-
ertheless, due to the observed favorable tendency, future analysis
including a higher number of patients and, eventually, random-
ized clinical studies, should be performed to further clarify these
observations.Table 1. Patients and transplant features
ASCT cohort Chemo cohortn5 10 n5 20Prior AIDS defining disease 43% 30% p5NS
Age at lymphoma diagnosis:
median (range)
40 (34-60.5) 43.5 (30-56.5) p5NSMale sex 7 (70%) 14 (70%) p5NS
Diffuse large B cell /
Plasmablastic
8 (80%) / 2
(20%)18 (90%) / 2
(10%)p5NSIPI at diagnosis (.2) 7 (70%) 14 (70%) p5NS
Ann Arbor stage at
diagnosis (.II)
9 (90%) 16 (80%) p5NSRituximab use 5 (50%) 10 (50%) p5NS
Number of treatment lines:
median (range)
1 (1-2) 1 (1-2) p5NSMonths from diagnosis to end
of chemo: median (range)5.8 (3.5-11) 4.3 (2.4-7.4) p5NS
